- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT01501032
Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients With Type 1 Diabetes (MD-Logic- Cont)
March 18, 2015 updated by: Rabin Medical Center
Inpatient Evaluation of the MD-Logic Artificial Pancreas System in Patients
The purpose of this feasibility study is to evaluate the MDLAP (MD-Logic Artificial Pancreas system)automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes.
The study will include 3 inpatient admissions (12-24 hr), which will include overnight sleep, over-bolus meal, under-bolus meal and exercise.
Study Overview
Status
Withdrawn
Conditions
Intervention / Treatment
Detailed Description
The purpose of this feasibility study is to evaluate the MDLAP (MD-Logic artificial pancreas system)automated insulin management system using continuous glucose monitoring (CGM) and subcutaneous insulin pump infusion in individuals with type 1 diabetes.
The study will include 3 inpatient admissions (12-24 hr), which will include overnight sleep, over-bolus meal, under-bolus meal and exercise.
During the the visits, meal boluses will be semi-automated, with manual meal announcement by the physician/nurse, automated bolus recommendation by the system, and automated delivery of the bolus following confirmation of the recommendation.
Between-meal insulin dosing will be fully automated.
Bolus confirmation by the physician/nurse will be requested by the closed loop controller only when it determines that carbohydrates may be necessary to avoid hypoglycemia following the bolus.
Study Type
Interventional
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
-
Petah-tikva, Israel, 49202
- Schneider Children's Medical Center
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
10 years to 63 years (Child, Adult, Older Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Clinical diagnosis of type 1 diabetes for at least one year and using an insulin pump for at least 6 months
- Age 12 to 65 years
- Hemoglobin A1c (HbA1c) between 5.0% and 10.5%, as measured with DCA2000 or equivalent device
- For females, not currently known to be pregnant
- Demonstration of proper mental status and cognition for the study
- An understanding of and willingness to follow the protocol and sign the informed consent or assent
Exclusion Criteria:
- Diabetic ketoacidosis in the past 6 months
- Severe hypoglycemia resulting in seizure or loss of consciousness in the 12 months prior to enrollment
- History of a seizure disorder (except hypoglycemic seizure).
- Coronary artery disease or heart failure.
- Cystic fibrosis
- Active infection
- A known medical condition that in the judgment of the investigator might interfere with the completion of the protocol
- A recent injury to body or limb, muscular disorder, use of any medication, any carcinogenic disease, or other significant medical disorder if that injury, medication or disease in the judgment of the investigator will affect the completion of the exercise protocol
- Current use of a beta blocker medication
- Hematocrit <30%
- Use of pseudoephedrine 48 hours prior to Clinical Research Center (CRC) admission
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: N/A
- Interventional Model: Single Group Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Closed Loop Control- MD-Logic
The MD-Logic artificial pancreas system will be used in conjunction with continuous glucose monitoring and insulin pump delivery to manage the subject's blood glucose.
|
The MD-logic artificial pancreas system is a closed loop control system using continuous glucose monitoring (CGM)and subcutaneous insulin pump infusion to mange glucose control in individuals with type 1 diabetes
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of glucose values 71-180 mg/dL of combined day and night readings during the first admission visit
Time Frame: Day 1
|
Day 1
|
|
Percent of subjects with blood glucose reading of 71-180 mg/dL 4 hours following the breakfast with a missed meal bolus
Time Frame: Day 1
|
Success is defined as >=40% subjects with a blood glucose in the 71-180 mg/dL range.
|
Day 1
|
Percent of subjects with blood glucose reading of 71-180 mg/dL 5 hours following the breakfast with a meal bolus 30% more than the recommended bolus amount
Time Frame: Day 2
|
Success is defined as >=50% subjects with a blood glucose in the 71-180 mg/dL range.
|
Day 2
|
Percent of subjects with a blood glucose nadir <=60 mg/dL following exercise
Time Frame: Day 3
|
Success is defined as less than 25% of subjects with a blood glucose nadir <=60 mg/dL.
|
Day 3
|
Overall frequency of hypoglycemia
Time Frame: day 3
|
Success defined as no subjects with severe hypoglycemia with a low blood glucose resulting in seizure, unconsciousness or the inability to treat oneself.
|
day 3
|
Overall frequency of hyperglycemia
Time Frame: Day 3
|
Success defined as no subjects with diabetic ketoacidosis (DKA).
|
Day 3
|
Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount
Time Frame: day 2
|
Success is defined as less than 5% of subjects have a peak blood glucose >400 mg/dL
|
day 2
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Percent of blood glucose values 71-180 mg/dL during the day (9:00AM-11:00PM) of the first admission visit
Time Frame: Day 1
|
Day 1
|
|
Percent of blood glucose values 70-180 mg/dL during the night (11:00PM-8:00AM) of the first admission visit
Time Frame: Day 1
|
Day 1
|
|
Percent of blood glucose values >400 mg/dL during the first admission visit
Time Frame: Day 1
|
Individual success is defined as no blood glucose values >400 mg/dL.
|
Day 1
|
Percent of blood glucose values <=60 mg/dL during the first admission visit
Time Frame: Day 1
|
No more than 33% of visits with blood glucose <=60 mg/dL
|
Day 1
|
Percent of subjects with a peak blood glucose >400 mg/dL following the breakfast with a missed meal bolus
Time Frame: Day 1
|
Success is defined as less than 5% of subjects have a peak blood glucose >400 mg/dL
|
Day 1
|
Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a missed meal bolus
Time Frame: Day 1
|
Success is defined as less than 15% of subjects have a nadir blood glucose <=60 mg/dL
|
Day 1
|
Percent of subjects with a nadir blood glucose <=60 mg/dL following the breakfast with a meal bolus 30% more than the recommended bolus amount
Time Frame: Day 2
|
Success is defined as less than 25% of subjects have a nadir blood glucose <=60 mg/dL
|
Day 2
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Sponsor
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start
October 1, 2013
Primary Completion (Actual)
December 1, 2014
Study Completion (Actual)
December 1, 2014
Study Registration Dates
First Submitted
December 14, 2011
First Submitted That Met QC Criteria
December 25, 2011
First Posted (Estimate)
December 29, 2011
Study Record Updates
Last Update Posted (Estimate)
March 19, 2015
Last Update Submitted That Met QC Criteria
March 18, 2015
Last Verified
March 1, 2015
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- rmc006385ctil
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetes Type 1
-
Poznan University of Medical SciencesUnknownDiabetes Mellitus Type 1 | Remission of Type 1 Diabetes | Chronic Complications of DiabetesPoland
-
Eledon PharmaceuticalsWithdrawnBrittle Type 1 Diabetes MellitusUnited States
-
National Institute of Allergy and Infectious Diseases...PPD; Rho Federal Systems Division, Inc.; Immune Tolerance Network (ITN)CompletedType 1 Diabetes Mellitus | T1DM | T1D | New-onset Type 1 Diabetes MellitusUnited States, Australia
-
Hoffmann-La RocheCompletedType 2 Diabetes, Type 1 DiabetesAustria, United Kingdom
-
Shanghai Changzheng HospitalRecruitingBrittle Type 1 Diabetes MellitusChina
-
Capillary Biomedical, Inc.TerminatedType 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Type I | Diabetes Mellitus, Insulin-Dependent, 1 | IDDMAustria
-
Capillary Biomedical, Inc.CompletedDiabetes Mellitus, Type 1 | Type 1 Diabetes | Type 1 Diabetes Mellitus | Diabetes Mellitus, Insulin-Dependent, 1Australia
-
AstraZenecaCompletedType 2 Diabetes Mellitus | Type 1 Diabetes MellitusUnited States
-
NYU Langone HealthNational Heart, Lung, and Blood Institute (NHLBI)Recruiting
-
Rabin Medical CenterDreaMed DiabetesTerminated
Clinical Trials on MD-logic artificial pancreas system
-
Rabin Medical CenterCompletedType 1 DiabetesIsrael, Germany, Slovenia
-
Rabin Medical CenterMedtronicCompleted
-
Rabin Medical CenterMedtronicCompleted
-
Rabin Medical CenterGIFWithdrawn
-
Rabin Medical CenterJuvenile Diabetes Research Foundation; University of Padova; Jaeb Center for... and other collaboratorsCompleted
-
Rabin Medical CenterNovo Nordisk A/S; DreaMedTerminated
-
Kochi UniversityUniversity of Tokushima; Oita UniversityUnknownCardiovascular Diseases | Pancreatic DiseaseJapan
-
Insulet CorporationCompleted
-
Insulet CorporationCompletedType 1 Diabetes MellitusUnited States